Tovanabutra Chokaew, Katanyoo Kanyarat, Uber Pichet, Chomprasert Kittisak, Sukauichai Sitthi
Radiation Oncology section, Chonburi Cancer Hospital, Chonburi, Thailand.
Department of Radiology, Faculty of Medicine, Vajira Hospital, Navamindradhiraj University, Bangkok, Thailand.
Asian Pac J Cancer Prev. 2020 Jan 1;21(1):119-125. doi: 10.31557/APJCP.2020.21.1.119.
The aim of this study was to compare Conventional fractionated radiotherapy (CFRT) and Hypofractionated radiotherapy (HFRT) in terms of treatment outcomes, such as in 5-year loco-regional recurrence free survival, disease free survival, overall survival, and distant metastatic free survival rates as well as toxicity.
We retrospectively analyzed the data obtained from 462 breast cancer patients who received complete adjuvant radiotherapy treatment between January 2012 and December 2014. One hundred twenty eight patients received CFRT 2 Gy daily fractions at a total dose of 48-60 Gy (group 1), while 334 patients received HFRT 2.65-2.67 Gy daily for 15-19 fractions at a total dose of 39.7-47.8 Gy 9 (grup 2). Treatment outcome such as 5-year loco-regional recurrence free survival, disease free survival, overall survival, and distant metastatic free survival rates as well as toxicity were measured and compared between two groups.
Median follow-up was 65.7 months (ranging from 45.1 to 95.2 months). Five-year loco-regional recurrence free survival rate was 96.1% in both CFRT and HFRT groups (p=0.993). Five-year disease-free survival rate of CFRT group was higher (68.8%), but this difference was not significant (HFRT =63.5%) (p=0.396). These were complied with 5-year overall survival rate (71.9% and 64.7%, p=0.385). Five-year distant metastatic free survival rate was 85.9% in CFRT group and 79.6% in HFRT group (p=0.169). No difference was observed between two groups in terms of toxicities, including changes in chest wall appearance, skin fibrosis, brachial plexopathy, arm edema, pulmonary fibrosis, and cardiovascular events.
The treatment outcomes of hypofractionated radiotherapy in the postmastectomy breast cancer patients is comparable to the outcomes of conventional treatment at the Chonburi Cancer Hospital as previously reported from other studies, and HFRT can be implemented in resource-limited settings.
本研究旨在比较常规分割放疗(CFRT)和大分割放疗(HFRT)的治疗效果,如5年局部区域无复发生存率、无病生存率、总生存率、远处转移无生存率以及毒性。
我们回顾性分析了2012年1月至2014年12月期间接受完整辅助放疗的462例乳腺癌患者的数据。128例患者接受CFRT,每日分割剂量2 Gy,总剂量48 - 60 Gy(第1组),而334例患者接受HFRT,每日剂量2.65 - 2.67 Gy,共15 - 19次分割,总剂量39.7 - 47.8 Gy(第2组)。测量并比较两组的治疗效果,如5年局部区域无复发生存率、无病生存率、总生存率、远处转移无生存率以及毒性。
中位随访时间为65.7个月(范围45.1至95.2个月)。CFRT组和HFRT组的5年局部区域无复发生存率均为96.1%(p = 0.993)。CFRT组的5年无病生存率较高(68.8%),但差异不显著(HFRT = 63.5%)(p = 0.396)。这与5年总生存率(71.9%和64.7%,p = 0.385)相符。CFRT组的5年远处转移无生存率为85.9%,HFRT组为79.6%(p = 0.169)。两组在毒性方面无差异,包括胸壁外观变化、皮肤纤维化、臂丛神经病变、手臂水肿、肺纤维化和心血管事件。
如先前其他研究报道,春武里癌症医院保乳术后乳腺癌患者大分割放疗的治疗效果与传统治疗效果相当,且大分割放疗可在资源有限的环境中实施。